We’re excited to announce that we’re exhibiting at the WHX Labs World Health Expo, Dubai from Feb 10-13, 2026! And we’re bringing our brand-new TB solution BactoSiA™. Stop by Molbio Diagnostic’s booth #SA.E01 to connect with us!
We invite you to join our talk – Devika Gholap, Chief Product Officer, OptraSCAN, Inc. will speak on “Implementation Science Considerations for Digitally Enabled Tuberculosis Microscopy” on Feb 11, 2026, at 1:30 PM GST in Clinical Microbiology Track.
The successful adoption of new diagnostic technologies in tuberculosis control depends not only on analytical performance but also on implementation feasibility within existing laboratory systems. Factors such as training, workflow integration, quality assurance, and data management play a critical role in real-world impact. This session will present an implementation science perspective on digitally enabled TB microscopy, examining how digital slide workflows and assisted image analysis can be introduced into routine laboratory practice. The presentation will discuss challenges, enablers, and evaluation metrics relevant to national TB programs and reference laboratories, with a focus on sustainability and scalability.
Devika Gholap, Chief Product Officer, OptraSCAN, Inc.
Devika Gholap is the Chief Product Officer at OptraSCAN, recognized in Forbes 30 Under 30 and known for driving innovation in digital pathology and AI-enabled diagnostics. With a background in Biomedical Engineering and an MBA from Columbia Business School, she has built her career around making advanced diagnostics accessible, efficient, and globally scalable. Her entrepreneurial journey began with a clear mission to bridge the diagnostic gap in pathology. She identified early that pathology had not evolved at the pace of other medical fields, and that digitization, cloud technology, and AI could dramatically improve accuracy, turnaround time, and global access. This vision led to the evolution of OptraSCAN from a hardware-centric company into a comprehensive digital pathology ecosystem.
OptraSCAN today offers whole-slide scanners, AI algorithms, virtual IHC staining, a global pathology cloud platform, telepathology solutions, and disease-focused diagnostic offerings such as cervical cancer, TB, and HER2. Under Devika’s leadership, the company has expanded into multiple international markets, strengthened its product portfolio, enhanced manufacturing and QC processes, and built robust regulatory and clinical capabilities. Key growth achievements include the launch of the world’s first pay-per-use scanning model, expansion of virtual staining technologies, development of next-generation algorithms, and significant global brand visibility through conferences, collaborations, and thought leadership. Looking ahead, Devika’s focus for the next 2–3 years is on scaling OptraSCAN’s global digital pathology ecosystem, advancing AI innovation, expanding virtual staining, strengthening cloud and cybersecurity infrastructure, deepening presence in high-growth markets, enabling large-scale assay-based diagnostics, and expanding training and e-learning networks.
Are you ready to experience BactoSiA™?
Please fill out the form below and complete all questions with an asterisk (*)
